The AAAAI/ACAAI JTF has published updated AD guidelines based on new available treatments and evidence-based recommendations.

Abrocitinib is efficacious and well tolerated in AD patients with or without allergic comorbidities.

Pain and pruritus are the main contributors to AD burden and poor health-related QoL.

Psoriasis patients with pruritis and related sleep distrubances showed a lower quality of life in all domains.

Researchers developed a PRESTO tool using clinical variables to predict PsA risk in PsO patients with reasonable accuracy.

The use of dupilumab in patients with AD did not significantly affect the results of patch tests for allergic contact dermatitis.

Roflumilast showed significant improvement in disease severity in 95% of plaque psoriasis patients by week 8.

Patients who have contracted Covid-19 may have a higher risk of developing psoriasis and other immune-mediated inflammatory diseases.